Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
Go back to Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients| CANADIAN SUPERIOR ENERGY, Inc. (NYSE: SNG) | Delayed: 0.67 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.67 | 52 Week High | $1.15 | |||
| Open | $32.59 | 52 Week Low | $0.46 | |||
| Day High | $0.67 | P/E | N/A | |||
| Day Low | $0.67 | EPS | $0.00 | |||
| Volume | 786,028 | |||||
